The invention relates to a monoclonal antibody capable of inhibiting c-met dimethyl ether or a separated part or functional derivative thereof, including: (a) a heavy chain including cdr-h1 (section ID No.1)；CDR-H2（ID No.2），CDR-H3 (section ID No.3)；(b) a light chain including cdr-l1 (section ID No.5)；CDR-L2（ID No.6），Cdr-l3 (section ID: 7)；(c) a bisagra region consisting of single amino acid sequences selected from our numbers 22-28 and 72-86. The antibody specifically binds to the C-methyl human receptor and specifically inhibits the thyroid activity of 500 enzymes of the receptor, which is useful in the treatment of cancer and any pathology related to overexposure of the receptor.REFERIDA A UN ANTICUERPO MONOCLONAL, O SU FRAGMENTO O DERIVADO FUNCIONAL DIVALENTE, CAPAZ DE INHIBIR LA DIMERIZACION DE c-MET, QUE COMPRENDE: A) UNA CADENA PESADA QUE COMPRENDE CDR-H1 (SEC ID NO:1), CDR-H2 (SEC ID NO:2), CDR-H3 (SEC ID NO: 3)； B) UNA CADENA LIGERA QUE COMPRENDE CDR-L1 (SEC ID NO: 5), CDR-L2 (SEC ID NO:6), CDR-L3 (SEC ID:7)； Y C) UNA REGION BISAGRA QUE COMPRENDE LAS SECUENCIAS DE AMINOACIODS SELECCIONADA DE SEC ID NO: 22 A 28 Y SEC ID NO:72 A 86. DICHO ANTICUERPO SE UNE ESPECIFICAMENTE AL RECEPTOR C-MET HUMANO, INHIBIENDO ESPECIFICAMENTE LA ACTIVIDAD DE TIROSINA QUINASA DE DICHO RECEPTOR SIENDO UTIL EN EL TRATAMIENTO DE CANCER Y CUALQUIER PATOLOGIA RELACIONADA CON LA SOBREEXPRESION DE DICHO RECEPTOR
